EUVIMEDEUVIMED entdecken
Multizentrische Studie

Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach

Aysenur Yaliniz, Mathieu Blouin, Marie-Élaine Métras, Marie-Christine Boulanger, Karine Cloutier, Marie-Hélène Dubé, Julie Autmizguine, Amélie Marsot

European Journal of Drug Metabolism and Pharmacokinetics · 2024

DOI: 10.1007/s13318-024-00913-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, 2024. Verfasst von Aysenur Yaliniz und 7 weiteren Autor:innen. Beteiligte Einrichtung: STP2 Laboratory, Faculty of Pharmacy, Université de Montréal, 2940 Chemin de Polytechnique, Montreal, QC, H3T 1J4, Canada. aysenur.yaliniz@umontreal.…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Vancomycin, Anti-Bacterial Agents, Drug Monitoring. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Réseau Mère-Enfant de la Francophonie, Faculté de pharmacie, Université de Montréal, Réseau de recherche en Santé Respiratoire du Québec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: An increase in Staphylococcus aureus infections has been reported in pediatric patients with cystic fibrosis (CF) over the last few years. This pathogen is commonly treated with vancomycin, an antibiotic for which therapeutic drug monitoring (TDM) is recommended. Updated guidelines were recently published regarding new targets of exposure for the TDM of vancomycin through a Bayesian approach, using population pharmacokinetic (popPK) models. OBJECTIVES: This study aims to assess the predictive performance of vancomycin popPK models in pediatric patients with CF and to recommend optimal initial dosing regimens based on simulations. METHODS: Patient data were collected from two centers in Canada, and a literature review was conducted to identify all published vancomycin popPK models for pediatric CF patients. External evaluation and simulations were performed according to patient and occasion of treatment. RESULTS: A total of 53 vancomycin concentrations were collected from six pediatric CF patients. Only two popPK models of vancomycin for pediatric CF patients were identified through the literature review. The external evaluation results for both centers combined revealed a population bias of 28.1% and an imprecision of 33.7%. A re-estimation of parameters was performed to improve predictive performance. The optimal initial dosing regimen was 15 mg/kg/dose administered every 6 hours according to the per occasion remodel. CONCLUSION: The predictive performance and identified optimal initial dosing regimens associated with the model were different depending on the data used, showing external evaluation's importance before implementing a model in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisVancomycinAnti-Bacterial AgentsDrug MonitoringModels, BiologicalHumansChildMaleAdolescentFemaleBayes TheoremStaphylococcal InfectionsChild, PreschoolCanadaDose-Response Relationship, Drug

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • STP2 Laboratory, Faculty of Pharmacy, Université de Montréal, 2940 Chemin de Polytechnique, Montreal, QC, H3T 1J4, Canada. aysenur.yaliniz@umontreal.ca.
  • Faculty of Pharmacy, Université de Montréal, Montreal, Canada. aysenur.yaliniz@umontreal.ca.
  • STP2 Laboratory, Faculty of Pharmacy, Université de Montréal, 2940 Chemin de Polytechnique, Montreal, QC, H3T 1J4, Canada.
  • Faculty of Pharmacy, Université de Montréal, Montreal, Canada.
  • Department of Pharmacy, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada.
  • Faculty of Pharmacy, Université Laval, Quebec, Canada.

Förderung

  • Réseau Mère-Enfant de la Francophonie
  • Faculté de pharmacie, Université de Montréal
  • Réseau de recherche en Santé Respiratoire du Québec
  • Fonds de Recherche du Québec - Santé

Zitieren

APA

Yaliniz, A., Blouin, M., Métras, M. É., Boulanger, M. C., Cloutier, K., Dubé, M. H., Autmizguine, J., & Marsot, A. (2024). Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-024-00913-4

Vancouver

Yaliniz A, Blouin M, Métras MÉ, Boulanger MC, Cloutier K, Dubé MH, et al. Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach. European Journal of Drug Metabolism and Pharmacokinetics. 2024. doi:10.1007/s13318-024-00913-4

BibTeX
@article{Yaliniz2024,
  author = {Yaliniz, Aysenur and Blouin, Mathieu and Métras, Marie-Élaine and Boulanger, Marie-Christine and Cloutier, Karine and Dubé, Marie-Hélène and Autmizguine, Julie and Marsot, Amélie},
  title = {Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach},
  journal = {European Journal of Drug Metabolism and Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s13318-024-00913-4}
}
Kostenlos starten →